journal article·2024-12

Synergistic Gas Therapy and Targeted Interventional Ablation With Size‐Controllable Arsenic Sulfide (As 2 S 3 ) Nanoparticles for Effective Elimination of Localized Cancer Pain

Yu Tang, Jiyun Zhang, Yuan Yuan, Kele Shen, Zhiyuan Luo, Luyu Jia, Xiaofeng Long, Chi Peng, Tian Xie, Xiaoyuan Chen, Pengfei Zhang

Small· Volume 20· Issue 51
Publisher page

Abstract

Abstract The elimination of localized cancer pain remains a globally neglected challenge. A potential solution lies in combining gas therapy with targeted interventional ablation therapy. In this study, HA‐As 2 S 3 nanoparticles with controlled sizes are synthesized using different molecular weights of sodium hyaluronate (HA) as a supramolecular scaffold. Initially, HA co‐assembles with arsenic ions (As 3+ ) via coordinate bonds, forming HA‐As 3+ scaffold intermediates. These intermediates, varying in size, then react with sulfur ions to produce size‐controlled HA‐As 2 S 3 particles. This approach demonstrates that different molecular weights of HA enable precise control over the particle size of arsenic sulfide, offering a straightforward and environmentally friendly method for synthesizing metal sulfide particles. In an acidic environment, HA‐As 2 S 3 nanoparticles release hydrogen sulfide(H 2 S) gas and As 3+ . The released As 3+ directly damage tumor mitochondria, leading to substantial reactive oxygen species (ROS) production from mitochondria. Concurrently, the H 2 S gas inhibits the activity of catalase (CAT) and complex IV, preventing the beneficial decomposition of ROS and disrupting electron transfer in the mitochondrial respiratory chain. Consequently, it is found that H 2 S gas significantly enhances the mitochondrial damage induced by arsenic nanodrugs, effectively killing local tumors and ultimately eliminating cancer pain in mice.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Sulfur Compounds in Biology · Nanoplatforms for cancer theranostics · Bone health and treatments

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Institute of Molecular Immunology School of Laboratory Medicine and Biotechnology Southern Medical University Guangzhou 510000 China

Innovation Research Institute of Traditional Chinese Medicine Shanghai University of Traditional Chinese Medicine Shanghai 200000 China

The Second Clinical Medical College Guangzhou University of Chinese Medicine Guangzhou 510120 China

Key Laboratory of Elemene Class Anti‐Cancer Chinese Medicines Engineering Laboratory of Development and Application of Traditional Chinese Medicines Collaborative Innovation Center of Traditional Chinese Medicines of Zhejiang Province Hangzhou Normal University Hangzhou Zhejiang 310000 China

Departments of Diagnostic Radiology Surgery Chemical and Biomolecular Engineering, and Biomedical Engineering Clinical Imaging Research Centre Nanomedicine Translational Research Program Yong Loo Lin School of Medicine and Faculty of Engineering National University of Singapore Singapore 119077 Singapore

Funding

National Natural Science Foundation of China · Basic and Applied Basic Research Foundation of Guangdong Province

References (77)

Show source-provided references
1. 10.1039/D1CS01148K10.1039/D1CS01148K ↗
2. 10.1002/EXP.2021001110.1002/EXP.20210011 ↗
3. 10.1002/EXP.2021000510.1002/EXP.20210005 ↗
4. 10.1002/smll.20230863910.1002/smll.202308639 ↗
5. 10.1016/j.nano.2015.08.00610.1016/j.nano.2015.08.006 ↗
6. Fan X. · Small · 2023 · 19
7. 10.1002/smll.20220443610.1002/smll.202204436 ↗
8. 10.1002/smll.20240163110.1002/smll.202401631 ↗
9. 10.1016/j.medj.2022.12.00110.1016/j.medj.2022.12.001 ↗
10. 10.1039/C7PY00112F10.1039/C7PY00112F ↗
11. Wang Z. · Nan Fang yi ke da xue xue bao= J. South. Med. Univ. · 2010 · 30 · 1903
12. 10.1002/adma.20220952910.1002/adma.202209529 ↗
13. 10.1002/adma.20231021810.1002/adma.202310218 ↗
14. 10.1002/adma.20231104310.1002/adma.202311043 ↗
15. 10.1002/adma.20231029810.1002/adma.202310298 ↗
16. 10.1093/annonc/mdp00110.1093/annonc/mdp001 ↗
17. 10.1200/JCO.2014.56.038310.1200/JCO.2014.56.0383 ↗
18. 10.1016/j.soncn.2019.04.00310.1016/j.soncn.2019.04.003 ↗
19. 10.1002/hed.2719910.1002/hed.27199 ↗
20. 10.1016/j.pain.2004.12.01810.1016/j.pain.2004.12.018 ↗
21. 10.1002/adfm.20190899910.1002/adfm.201908999 ↗
22. 10.1002/adma.20210578310.1002/adma.202105783 ↗
23. 10.7150/thno.4393210.7150/thno.43932 ↗
24. 10.1016/j.jpainsymman.2017.10.01710.1016/j.jpainsymman.2017.10.017 ↗
25. 10.1093/annonc/mdm05610.1093/annonc/mdm056 ↗
26. 10.1016/j.pain.2010.02.03510.1016/j.pain.2010.02.035 ↗
27. 10.1002/cncr.3238010.1002/cncr.32380 ↗
28. 10.1002/adma.20210865310.1002/adma.202108653 ↗
29. 10.1016/j.nantod.2021.10122310.1016/j.nantod.2021.101223 ↗
30. 10.3389/fbioe.2020.0068210.3389/fbioe.2020.00682 ↗
31. 10.1021/jacs.1c0975310.1021/jacs.1c09753 ↗
32. 10.1166/jbn.2022.322410.1166/jbn.2022.3224 ↗
33. 10.1016/j.actbio.2015.06.01910.1016/j.actbio.2015.06.019 ↗
34. 10.1002/anie.20220083010.1002/anie.202200830 ↗
35. 10.1002/smll.20220424410.1002/smll.202204244 ↗
36. 10.1002/adma.20220588110.1002/adma.202205881 ↗
37. 10.1002/adma.20230997210.1002/adma.202309972 ↗
38. 10.1002/adma.20200848110.1002/adma.202008481 ↗
39. 10.1007/978-3-319-18144-810.1007/978-3-319-18144-8 ↗
40. 10.1038/nrd242510.1038/nrd2425 ↗
41. 10.1002/adma.20221124110.1002/adma.202211241 ↗
42. 10.1089/ars.2013.530810.1089/ars.2013.5308 ↗
43. 10.1016/j.niox.2015.08.00410.1016/j.niox.2015.08.004 ↗
44. 10.1002/adfm.20231474210.1002/adfm.202314742 ↗
45. 10.1002/adfm.20230094110.1002/adfm.202300941 ↗
46. 10.1002/advs.20190351210.1002/advs.201903512 ↗
47. 10.7150/thno.4507910.7150/thno.45079 ↗
48. 10.1002/adma.20210403710.1002/adma.202104037 ↗
49. 10.1002/smll.20200293910.1002/smll.202002939 ↗
50. 10.1111/bph.1236910.1111/bph.12369 ↗
51. 10.1002/adfm.20200799110.1002/adfm.202007991 ↗
52. 10.1002/adma.20230109910.1002/adma.202301099 ↗
53. 10.1002/adfm.20231242910.1002/adfm.202312429 ↗
54. 10.1016/j.jconrel.2022.10.05510.1016/j.jconrel.2022.10.055 ↗
55. 10.1021/acsami.9b2280210.1021/acsami.9b22802 ↗
56. 10.1002/anie.20201223710.1002/anie.202012237 ↗
57. 10.1002/anie.20170136610.1002/anie.201701366 ↗
58. 10.1002/adma.20240405310.1002/adma.202404053 ↗
59. 10.1002/adfm.20210166010.1002/adfm.202101660 ↗
60. 10.1016/j.tips.2022.03.00310.1016/j.tips.2022.03.003 ↗
61. 10.1021/acs.accounts.2c0046210.1021/acs.accounts.2c00462 ↗
62. 10.1016/j.apsb.2019.06.00410.1016/j.apsb.2019.06.004 ↗
63. 10.3389/fphar.2021.80048110.3389/fphar.2021.800481 ↗
64. 10.1016/j.ijbiomac.2023.12599310.1016/j.ijbiomac.2023.125993 ↗
65. 10.1007/s12282-018-0875-310.1007/s12282-018-0875-3 ↗
66. 10.1016/j.carbpol.2020.11598110.1016/j.carbpol.2020.115981 ↗
67. 10.1002/adfm.20230655410.1002/adfm.202306554 ↗
68. 10.1002/adfm.20231354010.1002/adfm.202313540 ↗
69. 10.1016/S1535-6108(03)00109-010.1016/S1535-6108(03)00109-0 ↗
70. 10.3390/biom1112185010.3390/biom11121850 ↗
71. 10.1074/jbc.M20627320010.1074/jbc.M206273200 ↗
72. 10.3390/ijms2506316410.3390/ijms25063164 ↗
73. 10.1111/jipb.1277910.1111/jipb.12779 ↗
74. 10.1002/adfm.20221214110.1002/adfm.202212141 ↗
75. 10.1002/adfm.20230952410.1002/adfm.202309524 ↗
76. 10.18632/oncotarget.1473310.18632/oncotarget.14733 ↗
77. 10.1021/acsnano.3c0651110.1021/acsnano.3c06511 ↗